Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.

Ribavirin (RBV) is an essential component of most current hepatitis C (HCV) treatment regimens and still standard of care in the combination with pegylated interferon (pegIFN) to treat chronic HCV in resource limited settings. Study results in HIV/HCV-coinfected patients are contradicting as to whet...

Full description

Bibliographic Details
Main Authors: Helen Kovari, Stefan Russmann, Bruno Ledergerber, Daniel Müller, Margalida Rotger, Pablo Velli, Matthias Cavassini, Juan Ambrosioni, Andrea Bregenzer, Marcel Stöckle, Enos Bernasconi, Andri Rauch, Roberto F Speck, Swiss HIV Cohort Study
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4517877?pdf=render

Internet

http://europepmc.org/articles/PMC4517877?pdf=render

Similar Items